selected publications
- Reduction of renal activity retention of radiolabeled albumin binding domain‑derived affinity proteins using a non‑residualizing label strategy compared with a cleavable glycine‑leucine‑glycine‑lysine‑linker. Molecular medicine reports. 2024 Academic Article GET IT
- Efficacy of HER2-Targeted Intraperitoneal 225Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2023 Academic Article GET IT
- Phase I Trial of [99mTc]Tc-maSSS-PEG2-RM26, a Bombesin Analogue Antagonistic to Gastrin-Releasing Peptide Receptors (GRPRs), for SPECT Imaging of GRPR Expression in Malignant Tumors. Cancers. 2023 Academic Article GET IT
- Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model. International journal of molecular sciences. 2023 Academic Article GET IT
- Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [68Ga]Ga-BQ7812 for PET Diagnostic Imaging of Prostate Cancer: A Step towards Clinical Translation. Cancers. 2023 Academic Article GET IT
- Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT. Pharmaceutics. 2022 Academic Article GET IT
- Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules. Biomedicines. 2022 Academic Article GET IT
- Design, Synthesis, and Evaluation of Linker-Optimised PSMA-Targeting Radioligands. Pharmaceutics. 2022 Academic Article GET IT
-
HER3 PET Imaging: 68Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to 89Zr-Labeled Antibody and Antibody-Fragment-Based Tracers.
Cancers.
2021
Academic Article
GET IT
Times cited: 80 -
Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.
Cancers.
2021
Academic Article
GET IT
Times cited: 245 -
PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.
International journal of molecular sciences.
2021
Review
GET IT
Times cited: 19 -
Preclinical Evaluation of 99mTc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake.
International journal of molecular sciences.
2021
Academic Article
GET IT
Times cited: 17 -
The Use of a Non-Conventional Long-Lived Gallium Radioisotope 66Ga Improves Imaging Contrast of EGFR Expression in Malignant Tumours Using DFO-ZEGFR:2377 Affibody Molecule.
Pharmaceutics.
2021
Academic Article
GET IT
Times cited: 126 -
66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26.
Scientific reports.
2021
Academic Article
GET IT
Times cited: 12 - Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer. Pharmaceutics. 2021 Academic Article GET IT
-
Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.
Molecules (Basel, Switzerland).
2020
Academic Article
GET IT
Times cited: 7 -
Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of Cancer.
Pharmaceutics.
2020
Academic Article
GET IT
Times cited: 17 -
Investigation of a Pharmacological Approach for Reduction of Renal Uptake of Radiolabeled ADAPT Scaffold Protein.
Molecules (Basel, Switzerland).
2020
Academic Article
GET IT
Times cited: 5 -
Heterodimeric Radiotracer Targeting PSMA and GRPR for Imaging of Prostate Cancer-Optimization of the Affinity towards PSMA by Linker Modification in Murine Model.
Pharmaceutics.
2020
Academic Article
GET IT
Times cited: 60 -
Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
Pharmaceutics.
2020
Academic Article
GET IT
Times cited: 10 -
Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
International journal of molecular sciences.
2020
Academic Article
GET IT
Times cited: 19 -
Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules.
International journal of molecular sciences.
2020
Academic Article
GET IT
Times cited: 8 -
Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
International journal of molecular sciences.
2020
Academic Article
GET IT
Times cited: 6 -
On the prevention of kidney uptake of radiolabeled DARPins.
EJNMMI research.
2020
Academic Article
GET IT
Times cited: 70 -
Increase in negative charge of 68Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules.
Scientific reports.
2019
Academic Article
GET IT
Times cited: 13 -
Selection of an optimal macrocyclic chelator improves the imaging of prostate cancer using cobalt-labeled GRPR antagonist RM26.
Scientific reports.
2019
Academic Article
GET IT
Times cited: 15 -
Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.
Cancers.
2019
Academic Article
GET IT
Times cited: 87 -
Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody-DM1 Drug Conjugates.
Cancers.
2019
Academic Article
GET IT
Times cited: 49 -
Synthesis and Preclinical Evaluation of Radio-Iodinated GRPR/PSMA Bispecific Heterodimers for the Theranostics Application in Prostate Cancer.
Pharmaceutics.
2019
Academic Article
GET IT
Times cited: 13 -
Indirect Radioiodination of DARPin G3 Using N-succinimidyl-Para-Iodobenzoate Improves the Contrast of HER2 Molecular Imaging.
International journal of molecular sciences.
2019
Academic Article
GET IT
Times cited: 21 -
Trastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist 177 Lu-DOTAGA-PEG2 -RM26.
International journal of cancer.
2019
Academic Article
GET IT
Times cited: 30 -
Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake.
Scientific reports.
2019
Academic Article
GET IT
Times cited: 7 -
Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of 68Ga-Labeled Tracers.
International journal of molecular sciences.
2019
Academic Article
GET IT
Times cited: 21 -
Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
International journal of oncology.
2019
Academic Article
GET IT
Times cited: 27 -
Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111.
Scientific reports.
2019
Academic Article
GET IT
Times cited: 20 -
Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs.
Cells.
2018
Academic Article
GET IT
Times cited: 72 -
Radionuclide imaging of VEGFR2 in glioma vasculature using biparatopic affibody conjugate: proof-of-principle in a murine model.
Theranostics.
2018
Academic Article
GET IT
Times cited: 24 -
Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab.
Molecular pharmaceutics.
2018
Academic Article
GET IT
Times cited: 15 -
Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.
Scientific reports.
2018
Academic Article
GET IT
Times cited: 9 -
Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
International journal of oncology.
2017
Academic Article
GET IT
Times cited: 10